» Articles » PMID: 15192797

The Natural History of Chronic Hepatitis B Virus Infection

Overview
Journal Semin Liver Dis
Publisher Thieme
Specialty Gastroenterology
Date 2004 Jun 12
PMID 15192797
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Three stages of chronic hepatitis B virus (HBV) infection are recognized: the immune tolerant phase, the chronic hepatitis B phase, and the inactive hepatitis B carrier phase. Active liver disease is most often found in persons with elevated aminotransferase levels and HBV DNA levels >10(5) copies/mL. Possible risk factors for developing liver disease include older age, male gender, presence of hepatitis B e antigen (HBeAg), HBV genotype, mutations in the precore and core promoter regions of the viral genome, and coinfection with hepatitis D (delta) virus. All persons chronically infected with HBV should be followed every 6 to 12 months with aminotransferase levels. Those with elevated levels should be tested for HBeAg and its antibody (anti-HBe) as well as HBV DNA levels to determine if they are in need of further evaluation with a liver biopsy and are candidates for antiviral therapy. Future research will help clarify the outcome of chronic HBV infection.

Citing Articles

Unraveling the Complexity of Atypical Serological Profiles in Chronic Hepatitis B: Insights Into Disease Dynamics and Clinical Implications.

Barkay O, Erol S, Senbayrak S Cureus. 2023; 15(9):e44899.

PMID: 37814733 PMC: 10560487. DOI: 10.7759/cureus.44899.


Malignancy and viral infections in Sub-Saharan Africa: A review.

Diakite M, Shaw-Saliba K, Lau C Front Virol. 2023; 3.

PMID: 37476029 PMC: 10358275. DOI: 10.3389/fviro.2023.1103737.


Exploring the optimal vaccination strategy against hepatitis B virus in childhood (Review).

Kramvis A, Mammas I, Spandidos D Biomed Rep. 2023; 19(1):48.

PMID: 37383679 PMC: 10293880. DOI: 10.3892/br.2023.1631.


Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study.

Wei S, Hu M, Chen H, Xie Q, Wang P, Li H BMC Gastroenterol. 2022; 22(1):387.

PMID: 35978283 PMC: 9387004. DOI: 10.1186/s12876-022-02471-y.


Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study.

Wang C, Chang K, Lin R, Kuo M, Yang C, Tseng Y Medicine (Baltimore). 2020; 99(18):e19907.

PMID: 32358357 PMC: 7440314. DOI: 10.1097/MD.0000000000019907.